OBJECTIVE: Our designated obstetric OUD clinic offers opiate detoxification. If fully detoxed, naltrexone is offered. Naltrexone protocol requires the patient be opiate free for at least 7 days with 2 negative drug screens. A daily 50 mg dose is used that is adjusted near delivery. To date, only a few retrospective studies on naltrexone implant use during pregnancy are in print. The study objective was to prospectively evaluate the use of naltrexone in pregnancy. STUDY DESIGN: Prospective study that collected data on all pregnant women who started naltrexone after opiate detoxification. Data collection included GA at full detoxification, GA at naltrexone initiation, fetal response to the drug, pregnancy/newborn outcome, relapse rate, and paired maternal/cord blood levels for free naltrexone and 6-beta-naltrexol (20 patients). RESULTS: 108 pregnant patients started naltrexone during the study period. No relapses occurred in the 7-day no-treatment window prior to drug initiation. 82 (76%) patients were on naltrexone to delivery and no neonates had NAS. 4 newborns had NAS in the 26 cases that stopped naltrexone prior to delivery. Primary reasons for stopping naltrexone were headache (8) and "did not think they needed it" (11). 57 (53%) cases were started after 24 weeks gestation and had continuous fetal monitoring for 60 minutes during the first dose and no changes in FHR were seen. For the 51 cases < 24 weeks, no changes were seen in the FHR by auscultation or ultrasound during first dosage administration. 21 (19%) started naltrexone in the first trimester (<13 weeks) and no fetal anomalies occurred. No cases of SAB or IUFD occurred in the 108 pregnancies. 12 (11%) patients spontaneously delivered prior to 37 weeks gestation. Cord blood levels for naltrexone and 6-beta-naltrexol matched maternal levels (Table) ; no levels were elevated; and values were undetected if naltrexone was discontinued more than 60 hours prior to delivery. CONCLUSION: This is the first prospective study and largest to date on the use of naltrexone in pregnancy. The drug crosses the placenta; maternal and fetal levels are concordant; and the drug clears quickly. The drug is well-tolerated by both mother and fetus and newborns do not experience NAS if the mother is on naltrexone to delivery. These data demonstrate that the use of naltrexone is a viable option for managing OUD in pregnancy. 
OBJECTIVE:
To report the first 18 months outcome data for a designated obstetric OUD Clinic. The program offers detoxification through outpatient tapering, inpatient detoxification, and offers the Bridge Device in selected patients. Intense behavioral health is included. STUDY DESIGN: Prospective study reporting outcome data on compliant patients for the first 18 months of a designated OUD Clinic. Collected data include: number of patients accepting taper/ detoxification, NAS rates, relapse rates at delivery, and pregnancy outcome. Data on Bridge Device use are reported. RESULTS: 367 compliant patients were managed during the study period. All patients were initially stabilized on MAT (buprenorphine or methadone). Once stable, all are given the option of tapering/detoxification. 286 (78%) chose this option and 152 (53%) were fully detoxed. Of the 152, 126 (83%) were drug free at delivery and no NAS occurred. 26 (17%) went back to opioids (18 to MAT, 8 to illicit opioids). The relapse rate at delivery for those fully detoxed was 5%. 116 were on MAT (81 chose MAT at the start and 35 began tapering but changed back to MAT). The Table shows the NAS rates per patient category. The NAS rate for those on MAT was 77% (89/116) and for those that tapered by delivery (but did not fully detox) was 55% (55/99). No losses occurred in the tapered/detoxed group. The Figure provides an overview of the primary OUD clinic protocol. The spontaneous preterm birth rate was 12% in the NAS group and 11% in the No NAS group. The Bridge Device is an FDA approved small percutaneous nerve field stimulator that helps minimize withdrawal symptoms. Devices were purchased by the clinic and the manufacturer did not sponsor and was not affiliated with the study. 14 patients had the device applied with 10 complete successes (71%) to naltrexone. Antenatal monitoring showed no changes in fetal status during use of the device. CONCLUSION: This is the first study to prospectively report outcome data on a designated OUD clinic that offers detoxification during pregnancy. This is also the first report on the use of the Bridge Device in pregnancy showing promising results. With a structured program that includes behavioral health and offers the option of detoxification, fetal risks are negligible; relapse rates by delivery are low; and NAS rates are greatly decreased.
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